Skip to content

Stress Urinary Incontinence and Sarcopenia in Postmenopausal Osteoporosis

Stress Urinary Incontinence and Sarcopenia in Postmenopausal Osteoporosis: The Intersection of Muscle Loss and Pelvic Dysfunction

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06655701
Enrollment
100
Registered
2024-10-23
Start date
2024-11-15
Completion date
2025-01-15
Last updated
2024-12-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis, Postmenopausal

Brief summary

The primary aim of our study is to evaluate the presence of stress urinary incontinence in postmenopausal patients with and without osteoporosis, determine its impact on quality of life, and explore its relationship with sarcopenia.

Detailed description

One hundred postmenopausal women, aged 50-75, who applied to the Physical Therapy and Rehabilitation outpatient clinic at Beylikdüzü State Hospital and have Dual-X-ray Absorptiometry (DXA) measurements taken within the last 6 months, including both osteoporotic and non-osteoporotic patients, will be included in the study. Sociodemographic data such as age, gender, height, weight, and BMI will be recorded. DXA results, including femoral neck and L1-L4 T-scores and BMD values, will be obtained. Patients will be asked about osteoporosis treatment, presence of fecal incontinence, constipation, and medication use. Stress urinary incontinence will be determined through a questionnaire, and its impact on quality of life will be assessed using the Incontinence Quality of Life Scale. In the second phase, sarcopenia will be evaluated according to the Asian Working Group for Sarcopenia (AWGS) criteria by assessing skeletal muscle mass (via bioelectrical impedance analysis), handgrip strength, and the 5-times sit-to-stand test.

Interventions

DIAGNOSTIC_TESTNo intervention

No intervention

Sponsors

Beylikduzu State Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
50 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Postmenopausal women with DXA measurements performed within the last 6 months. * Based on DXA measurements: Femoral neck and L1-L4 T-scores of -1 and above will be included in the control group (non-osteoporotic). Femoral neck and L1-L4 T-scores of -2.5 and below will be included in the osteoporosis group. * Aged 50-75 years

Exclusion criteria

* Refusal to participate in the study. * History of neurological diseases, infections, surgeries, or trauma that could cause urinary incontinence or muscle loss. * Presence of psychiatric disorders. * Cognitive impairments. * Use of medications that could affect the study results.

Design outcomes

Primary

MeasureTime frameDescription
Presence of Stress Urinary Incontinence:0 dayStress urinary incontinence (SUI) is the involuntary leakage of urine during physical activities that increase abdominal pressure, such as coughing, sneezing, or lifting. In this study, the presence of SUI will be determined through a questionnaire that asks participants about symptoms and frequency of urine leakage during such activities.
Incontinence Quality of Life Scale (I-QOL):0 dayThe I-QOL is a validated questionnaire that measures the impact of urinary incontinence on a patient's quality of life. It assesses how incontinence affects daily activities, social interactions, and emotional well-being. Higher scores indicate better quality of life, while lower scores suggest that incontinence has a more significant negative impact on the patient's day-to-day functioning.
Skeletal Muscle Mass:0 dayMeasured by bioelectrical impedance analysis (BIA), this assesses the amount of muscle tissue in the body. Low skeletal muscle mass indicates sarcopenia.
Handgrip Strength0 dayThis is a simple test to measure muscle strength. Reduced handgrip strength is a sign of sarcopenia.

Countries

Turkey (Türkiye)

Contacts

Primary ContactBüşra Şirin Ahısha, MD
bsrn080@gmail.com(0212) 856 27 40

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026